If this email is not displaying properly or to share with a colleague, please View as Webpage
Telemedicine: Getting Started,
Regulations and Privacy Issues
Time: 3:00 pm ET
Date: Friday, March 27, 2020
Presenter: William Morrone, MD,DO, MS, MPH, DABAM, FACOFP, DAAPM
Sponsoring organization: American Osteopathic Academy of Addiction Medicine (AOAAM)

Webinar description: The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, was enacted by Congress on March 6, 2020. As a result, this allowed broader use of and payment for telehealth services for Medicare beneficiaries during the emergency period as defined under the legislation. These recent changes in telemedicine regulations open new opportunities in patient assessment for Medications for Addiction Treatment for Opioid Use Disorders.

Many communities are adopting telehealth as one way to address gaps in access to treatment for mental and substance use disorders for Rural, Urban, Tribal, Limited-Transportation, Emergency Medical Crisis Disposition and Justice-Involved Populations.
This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will present ways to incorporate telemedicine into treatment programming for substance use disorders, including how to evaluate and expand access to medications for addiction treatment (MAT) using telemedicine, types of telehealth provider settings, implementation of PCSS best practices and evolving barriers. Billing codes will also be addressed.
Together we CAN make a difference!
If you would like to sign up for ORN's newsletters please contact jane@aaap.org with the subject line: Please add me to the ORN Newsletter.

orn@aaap.org 401 270-5900
Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.